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Background: Since 2007, the Australian Know your numbers (KYN) program has been used in community settings
to raise awareness about blood pressure and stroke. In 2011, the program was modified to include assessment for
type 2 diabetes risk. However, it is unclear which approach for assessing diabetes risk in pharmacies is best. We
compared two methods: random (non-fasting) blood glucose testing (RBGT); and the Australian type 2 diabetes
risk assessment tool (AUSDRISK); according to 1) identification of ‘high risk’ participants including head-to-head
sensitivity and specificity; 2) number of referrals to doctors; and 3) feasibility of implementation.
Methods: 117 Queensland pharmacies voluntarily participated and were randomly allocated to RBGT and AUSDRISK
or AUSDRISK only. Although discouraged, pharmacies were able to change allocated group prior to commencement.
AUSDRISK is a validated self-administered questionnaire used to calculate a score that determines the 5-year risk of
developing type 2 diabetes. AUSDRISK (score 12+) or RBGT (≥5.6 mmol/I) indicates a high potential risk of diabetes.
Median linear regression was used to compare the two measures. Staff from 68 pharmacies also participated in a
semi-structured interview during a site visit to provide feedback.
Results: Data were submitted for 5,483 KYN participants (60% female, 66% aged >55 years, 10% history of diabetes).
Approximately half of the participants without existing diabetes were identified as ‘high risk’ based on either RBGT or
AUSDRISK score. Among participants who undertook both measures, 32% recorded a high RBGT and high AUSDRISK.
There was a significant association between RBGT and AUSDRISK scores. For every one point increase in AUSDRISK
score there was a half point increase in RBGT levels (coefficient 0.55, 95% CI: 0.28, 0.83). Pharmacy staff reported that
AUSDRISK was a simple, low cost and efficient method of assessing diabetes risk compared with RBGT, e.g. since
management of sharps is not an issue.
Conclusions: In a large, community-based sample of Australians about half of the participants without diabetes were
at ‘high risk ‘of developing diabetes based on either AUSDRISK or RBGT results. AUSDRISK was considered to be an
acceptable method for assessing the risk of diabetes using opportunistic health checks in community pharmacies.
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Table 1 AUSDRISK: risk of developing type 2 diabetes
within 5 years
Risk category Score* 5-year risk of developing
type 2 diabetes*
2011 KYN diabetes
(N = 1,969)n (%)
Low ≤ 5 1 person in every 100 251 (13)
Intermediate
Intermediate 6 – 8 1 person in every 50 311 (16)
Intermediate 9 – 11 1 person in every 30 416 (21)
High
High 12 –15 1 person in every 14 526 (27)
High 16 - 19 1 person in every 7 280 (14)
High 20+ 1 person in every 3 185 (9)
*Source: adapted from: http://www.health.gov.au/internet/main/publishing.nsf/
Content/chronic-diab-prev-aus.
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Diabetes mellitus (diabetes) and particularly type 2 dia-
betes is considered a global epidemic [1]. In Australia, the
number of people diagnosed with diabetes has more than
doubled during the past two decades from 1.5% (1989-90)
to 4.1% (2007-08) [2]. Diabetes is an independent risk
factor for cardiovascular disease (CVD). The main types of
CVD are coronary heart disease, heart failure, cardiomy-
opathy and stroke [3]. About 11.7 million (95%) adult
Australians have at least one of the major modifiable risk
factors for stroke [4] including high blood pressure (BP),
diabetes, high cholesterol, smoking, alcohol, poor diet,
heart disease, obesity, atrial fibrillation, sleep disorders, ca-
rotid stenosis and inadequate physical activity [5]. Further-
more, knowledge of CVD risk factors is poor amongst
survivors of stroke who continue to be at high risk of
further events [6].
Recently, there has been a focus on increasing dia-
betes awareness since diabetes can be easily prevented
by medication or lifestyle changes. Health promotion
programs such as the Finnish Diabetes Prevention Pro-
gram [7], United States Diabetes Prevention Program
[8], the Australian Greater Green Triangle Diabetes
Prevention Program [9] and Life! program [10] have
been established to identify people at risk of diabetes.
Early identification of diabetes and risk factors for dia-
betes means that early management and prevention
programs can be provided, to reduce the potential for
serious complications [11-15].
Diabetes is commonly diagnosed by either a fasting
blood test or a non-fasting random blood glucose test
(RBGT) taken anytime during the day. The fasting blood
test is more accurate, but more time consuming and
costly, and cannot be performed opportunistically. In con-
trast the RBGT performed by doing a finger prick test
provides an immediate result and can be used to indi-
cate increased risk of diabetes (http://www.nlm.nih.gov/
medlineplus/ency/article/003482.htm). In a study con-
ducted by Krass et al. [16] it was found that implementation
of a pharmacy screening service based on an initial risk as-
sessment followed by a finger prick test was more cost ef-
fective in terms of numbers diagnosed with diabetes than
a risk assessment only. The cost difference was driven
by lower referral rates and the higher uptake of referrals
following the finger prick test. However, the tick test
used in this study for diabetes risk assessment was not
a comprehensive diabetes risk assessment. This test,
which predated the availability of current risk assess-
ment tools, did not assess lifestyle factors such as smok-
ing, diet or activity levels and there were no clinical
measures such as waist circumference.
Diabetes risk calculation tools [17] have also been devel-
oped in the Netherlands, Thailand, Denmark, Germany,
America and Finland. The most commonly used tool foridentification of individuals eligible for diabetes preven-
tion programs appears to be the FINDRISC [9]. In 2008,
the International Diabetes Institute (Baker IDI) as part
of the Council of Australian Governments initiative to
reduce the risk of diabetes, developed and validated
the Australian Type 2 Diabetes Risk Assessment Tool
(AUSDRISK). This is a self-administered screening ques-
tionnaire [18] (Table 1) which calculates a score that can
determine a broad level of risk of individuals developing
diabetes within the next five years. The score takes into
account age, gender, ethnicity, family and BP history,
smoking status, diet, level of physical activity and waist
measurement [18].
Since 2007, the National Stroke Foundation (NSF) has
undertaken a community-based awareness program for
BP and other stroke risk factors [19,20] called ‘Know
your numbers (KYN)’. In 2011, the NSF piloted an en-
hanced KYN program (Pilot KYN Diabetes Program)
which essentially included the use of AUSDRISK and
RBGT. This program provides an opportunity for partic-
ipants to identify risk factors for stroke and diabetes that
are potentially modifiable and associated with health re-
lated behaviours (e.g. physical inactivity) or biomedical
factors (e.g. high BP) [21]. However, it is unclear how
best to measure risk of diabetes in a community based
setting. In this pilot study, we aimed to compare two
methods for assessing diabetes risk in pharmacy settings
in Australia: random (non-fasting) blood glucose testing;
and the Australian Type 2 diabetes risk assessment tool;
according to 1) identification of ‘high risk’ participants
including head-to-head sensitivity and specificity; 2)
number of referrals to doctors; and 3) feasibility of im-
plementation in pharmacy.
Methods
Pilot KYN diabetes program
The Queensland KYN program delivered in community
pharmacies was modified in 2011 to include a free diabetes
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pants. A sample of KYN pharmacies in Queensland
agreed to participate in the pilot study (Figure 1). These
pharmacies offered the KYN program all year round on
a permanent basis. The pharmacies were initially ran-
domly allocated to provide one or two diabetes riskInvitation to Queens
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setting in Australia. The Group 1 pharmacies provided
BP testing, RBGT and AUSDRISK. The Group 2 phar-
macies provided BP testing and AUSDRISK only.
All staff involved in delivering the program underwent
compulsory online training. The purpose of the training
was to equip staff with appropriate background know-
ledge on stroke, diabetes and the risk factors for diabetes
for CVD and provide them with clear guidelines on how
to complete each of the components of the health check
appropriately and safely. The training module took
approximately 30 minutes to complete for pharmacies in
Group 2 and 40 minutes for Group 1. An extra 10 mi-
nutes were required for Group 1 in order to provide infor-
mation on risk management and infection control
practices in relation to RBGT. Evaluation of the training
by the participants indicated that the online training was
well structured and comprehensive with sufficient and ap-
propriate content to meet the needs of the staff providing
the health checks. With respect to the format, all partici-
pants who received training commented that the program
was easy and straight forward to follow. Continuous Pro-
fessional Development (CPD) points were provided for
those who completed the training.
Identification of ‘high risk’ participants requiring
further review
Any person who registered was included in the KYN Pilot
Program. There were no eligible age range restrictions (with
the exception of being 18 years or more) and participants
did not have to complete a BP check. The KYN Program is
targeted to people 45 years or more with training materials
but this was not enforced (Figure 1). For the purposes of
this paper, the term ‘high risk’ was used to classify regis-
trants who should have been advised by pharmacists, as
part of the KYN program, to seek further review and as-
sessment of their risk of developing diabetes or CVD (i.e. if
BP ≥140/90 mm Hg). The definitions for high risk of dia-
betes or BP was in keeping with Australian clinical guide-
line recommendations [22] (e.g. Royal Australian College of
General Practitioners guideline for diabetes management in
general practice endorsed by Diabetes Australia http://
www.racgp.org.au/your-practice/guidelines/diabetes/) avail-
able at the time this study was undertaken. Participants
were classified as ‘high risk’ of developing diabetes
within the next 5 years if they had an AUSDRISK score
(12+) or RBGT (≥5.6 mmol/I). These risk classifications
were agreed by the KYN Advisory Committee which had
representation from Diabetes Australia, Pharmacy Guild
of Australia, NSF, pharmacists, clinical experts and re-
searchers. The participants who were identified as being
‘high risk’ were provided with a standard letter for their
local doctor which included their risk assessment results
undertaken as part of the KYN program.Sensitivity and specificity of AUSDRISK and RBGT
In order to measure the discrimination potential of
AUSDRISK and RBGT we mapped the consistency of
AUSDRISK and RBGT scores for people who undertook
both measures using the AUSDRISK as the “reference
standard”. Based on the available data and its distribution
features median regression with bootstrapping adjusting
for age and gender was used to compare the RBGT levels
with AUSDRISK scores. Further analyses included calcu-
lating the sensitivity, specificity, positive and negative pre-
dictive value for all participants and by specific age groups
(<55 years and 55 years or more).
Quantitative diabetes risk data collection and analyses
All pharmacies collected data on a registration log. People
who registered to have their risk of diabetes and BP mea-
sured as part of the Pilot KYN Diabetes Program were
asked to provide basic demographic information, such as
age, gender, history of diabetes and or high BP. The regis-
tration log was also used to record the results of risk assess-
ments (AUSDRISK score and or RBGT level), BP readings
(systolic and diastolic blood pressure), and whether a refer-
ral to a general practitioner had been recommended for
‘high risk’ participants by the pharmacy staff.
Chi-square test for categorical variables was used to
compare groups for age, gender, ‘high risk’ categories and
number of referrals. Shapiro-Wilk test was performed to
test data for normality. Median and quartiles (25th and
75th) values were calculated for systolic and diastolic BP
readings, AUSDRISK and blood glucose scores. Kruskal-
Wallis test was used to compare Group 1 and Group 2.
Level of significance was set up at p < 0.05. All quantita-
tive analyses were performed using Intercool STATA
12.1 for Windows software (Stata Corp PL, 2013).
Feasibility of implementation in pharmacy
As part of the evaluation for the pilot a NSF project officer
(AH) collected qualitative data during site visits to pharma-
cies (Additional file 1). A detailed semi-structured interview
scheduled was developed (AH, DC, MK, RJ). The interview
schedule included both open and closed questions relating
to feedback on the pilot program. For example, there were
questions to explore the impact on staff time and resources,
space to conduct the KYN Program, safety considerations,
use of consumables, feedback on procedures and sustain-
ability of undertaking the different diabetes risk assess-
ments, where applicable.
All participating pharmacies were contacted to complete
the interview. To be eligible for an interview, a pharmacy
needed to have commenced delivering the program.
The primary contact in the pharmacy responsible for
implementation of the pilot program ("the champion"
who was usually the pharmacist or pharmacy assistant)
was requested to participate in the interview. The
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ity and the local context. The same researcher (AH)
conducted all the interviews. The data were directly re-
corded on a paper-based interview schedule by the inter-
viewer (AH). After which, de-identified data were then
entered into SurveyMonkey (http://www.surveymonkey.
com) for ease and accuracy of recording.
The qualitative free text data were then transferred to
Excel (Microsoft Office Corp, 2010) and subjected to
thematic analysis. Using an inductive approach for the
analysis, a coding tree outlining the major themes was
developed and used to systematically code and then ana-
lyse the text responses. Responses were independently
coded by two researchers (AH and TP) and then the re-
sults were cross-checked. Any discrepancies noted in the
coding were discussed and resolved. Once no new infor-
mation was being elicited from the completed interviews
they were ceased since saturation of information had
been reached [23].
Ethics approvals for the evaluation were provided by
the Austin Health Human Research Ethics Committee
(H2007/03028) and Queensland Health Central Office
Human Research Ethics Committee (HREC/11/QHC/8).
Results
Participation of pharmacies
Overall 117 pharmacies were randomly allocated to pro-
vide one or two diabetes risk assessment measures in
addition to a BP measurement (Figure 1 and Table 2) as
part of conducting their KYN program between May
and September in 2011. The participation rate and num-
ber of participants per site was greater in Group 1 than
Group 2 pharmacies (Figure 1). Nearly all participants at
pilot pharmacies had a BP measurement recorded, while
one in three participants had a diabetes risk assessment
recorded.
Profile of participants
Data were returned for 5,483 KYN health checks (Figure 1).
More females participated in the Pilot KYN Diabetes
Program compared to males (Table 2). This level of par-
ticipation by gender was consistent across the various age
groups, and about two-thirds of the participants were aged
55 years or more. There were no age or gender differences
between participants attending Group 1 and 2 pharmacies.
Over half (58%) of participants were opportunistically
‘passing by’ the pharmacy which motivated their decision
to have a KYN health check.
Just under half (47%) of participants recorded a high
BP (≥140/90 mm Hg) (Table 2). Of those participants
with a high BP reading recorded, 23% reported no his-
tory of high BP and 66% were referred to their general
practitioner for further assessment (Table 2). One in ten
participants reported a history of diabetes. Participantsattending Group 2 pharmacies were more likely to report
a history of diabetes (16%) than participants attending
Group 1 pharmacies (11%, p < 0.05).
Eligible participants (excluding those with a history of
diabetes) attending Group 1 pharmacies were more
likely to complete AUSDRISK (39%) than participants
attending Group 2 pharmacies (31%, p < 0.05). BP testing
was undertaken by nearly all participants in Group 1
(97%) and Group 2 (98%) pharmacies.
Identification of ‘high risk’ participants
Overall 1,969 participants without a reported history of
diabetes had an AUSDRISK assessment undertaken.
Table 2 shows that 50% of these participants had high
AUSDRISK scores. Figure 2 shows the proportion of
people by age group within various AUSDRISK categor-
ies. Males were more likely to have a high AUSDRISK
score than females (AUSDRISK 12+: males 58%, females
46%, p < 0.001). There were no differences between partic-
ipants attending Group 1 and 2 according to AUSDRISK
scores.
Overall 1,288 participants without a reported history
of diabetes had a RBGT. Fifty-three per cent of these
participants had a high RBGT level. There was no differ-
ence between RBGT level according to gender (RBGT
level ≥5.6 mmol/l: males 54%, females 53%, p = 0.55).
Figure 2 shows the proportion of people by age group
within ‘high risk’ RBGT categories.
Referral of participants with ‘high risk’ of diabetes to
general practitioners
As part of the KYN Program, pharmacists were educated
that all participants determined to be at ‘high risk’ of
diabetes should be referred to their general practitioner
for further assessment. However, approximately one-
third of participants identified as having a ‘high risk’ of
diabetes were not referred to their general practitioner.
However, we do not know if participants were not re-
ferred because they were already seeing a doctor for on-
going monitoring of these risk factors. Participants
attending Group 1 pharmacies were less likely to be rec-
ommended to see their general practitioner for further
assessment if they were at ‘high risk’ of diabetes com-
pared to participants attending Group 2 pharmacies
(Group 1 65%, Group 2 74%, p = 0.003).
Sensitivity and specificity
Overall, 1,121 participants without a history of diabetes
had both diabetes risk assessment measures (RBGT and
AUSDRISK). About one third of participants (369/1,121)
were identified at high risk of diabetes (by both AUSDRISK
and RBGT). Of the 589 participants with high AUSDRISK
score, 369 (63%) also had a high RBGT level and 220
(37%) had a normal RBGT level. Of the 532 participants
Table 2 Comparison of people tested in the KYN diabetes

















3,494 1,989 5, 483
Demographics
Female 2,023 (59) 1,203 (62) 3,266 (60)
Age 55 years or more 2,233 (66) 1,305 (67) 3,538 (66)
Do you have diabetes?
Yes 282 (11) 248 (16)* 530 (13)
No 1,956 (76) 1,164 (74) 3,120 (75)
Not sure 334 (13) 164 (10) 498 (12)
AUSDRISK score
Median (Q1, Q3) 12 (8, 15) 12 (8, 15) 12 (8, 15)
Low (<6) 158 (12) 93 (15) 251 (13)
Intermediate (6-11) 514 (38) 213 (34) 727 (37)
High (12+) 675 (50) 316 (51) 991 (50)
12-15 351 (26) 175 (28) 526 (27)
16-19 193 (14) 87 (14) 280 (14)
20+ 131 (10) 54 (9) 185 (9)
RBGT
Median (Q1, Q3) 5.8 (5.0, 6.9) - 5.8 (5.0, 6.9)
Normal (less than
5.6 mmol/l)
602 (47) - 602 (47)
High (5.6 mmol/l or
more)
686 (53) - 686 (53)
‘High risk’ of diabetes1 818 (74)* 316 (51) 1,134 (66)
BP readings
Systolic median (Q1, Q3) 135 (123,149) 136
(123,150)
135 (123,150)
Diastolic median (Q1, Q3) 81 (73, 89) 81 (73, 90) 81 (73, 90)
BP categories#
Normal 553 (16) 290 (15) 843 (16)
High-normal 1,272 (37) 707 (36) 1,979 (37)





1,065 (38)* 540 (33) 1,605 (36)
Referral to GP 1,441 (49)* 682 (37) 2,123 (44)
Recorded High BP check
Reported no history
of high BP
337 (25)** 174 (21) 511 (23)
Referral to GP
Table 2 Comparison of people tested in the KYN diabetes
program by group 1 (BP/AUSDRISK/RBGT) and group 2
(BP/AUSDRISK) (Continued)









BP: blood pressure; AUSDRISK: Australian Type 2 Diabetes Risk Assessment
Tool; Q1: 25th percentile; Q3: 75th percentile; High normal: 120-139/80-89
mm Hg; High: ≥140/90 mm Hg; ‘1; ‘High risk’ of diabetes (AUSDRISK score 12+
or RBGT ≥5.6 mmol/I); *p < 0.05 and **p < 0.07; #isolated systolic BP not reported
since this represents <0.3% of data.
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also had a high RBGT level and 288 (54%) had a normal
RBGT level.
Of the participants who undertook both measures,
33% had both high RBGT and high AUSDRISK; 20%
normal RBGT and high AUSDRISK; 22% high RBGT and
low AUSDRISK; 26% normal RBGT and low AUSDRISK.
Using median linear regression with bootstrapping
(Figure 3) adjusting for age and gender we showed that for
every one point increase in AUSDRISK score there was a
half point increase in RBGT levels (coefficient 0.55, 95%
CI; 0.28, 0.83). Using AUSDRISK as the reference standard
the sensitivity and specificity of the RBGT test was low
(Table 3). The AUSDRISK score was less specific for age
group (55+ years).
Feasibility of implementation in pharmacy
Qualitative feedback was obtained from 68 pharmacy
staff: 38 in Group 1 and 30 in Group 2. Respondents
were either a pharmacist or pharmacist assistant. The
major themes that emerged from the interviews related
to time requirements, staff competency, the procedure
itself, and referrals to general practitioners (Table 4).
Aspects such as limited staff and consumer time and
staff training reportedly affected the number of partici-
pants who received a diabetes risk assessment in both
Groups:
“Time impacts our ability to complete the entire health
check…”“Customers are usually very rushed……therefore [they are]
more likely to just want to have a BP check…..”
However, it was generally perceived that the AUSDRISK
was able to be performed by a pharmacy assistant unlike
the RBGT in many pharmacies “…some PAs [pharmacy as-
sistants] are not confident with BGT and are not interested
in learning”. Respondents also felt the AUSDRISK was
safer to perform, less invasive, less time consuming, and





































Low/Intermediate AUSDRISK (AUS) or Normal RBGT High risk
Figure 2 High risk scores (AUSDRISK and RBGT) by age groups.
F
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the storage and cost of all consumables required for
the blood glucose test makes it difficult”“Need to take the customer away to a private
consulting room [for RBGT]”
Discussion
The Pilot KYN Diabetes Program was successful in com-
paring the feasibility of two methods for assessing dia-
betes risk in a community setting. Both methods were
successful in being able to identify people in the com-
munity with an increased risk of developing diabetes



















igure 3 Relationship of AUSDRISK and random blood glucose test min two participants were at risk of developing diabetes
(50% of participants had high AUSDRISK score and 55%
a high RBGT levels). These findings suggest important
implications for a program such as KYN and demon-
strate the need for improved awareness, detection and
management of people at risk of type 2 diabetes. The
AUSDRISK tool was more acceptable to staff than pro-
viding the combined testing and resulted in more refer-
rals of participants with ‘high risk’ of diabetes to general
practitioners. The Pilot KYN Diabetes Program provided
the opportunity for over 2,000 participants to improve
their awareness of diabetes as a risk factor for stroke and
other CVD risk factors. The KYN Program also resulted
in over 645 people being recommended to seek further20 30
SK score
Fitted values
easures using median linear regression.
Table 3 Sensitivity, specificity and predictive values of
RBGT (≥5.6 mm/mol) to predict risk of diabetes at











Sensitivity 63 (59, 67) 63 (54, 71) 63 (58, 67)
Specificity 54 (50, 58) 62 (56, 68) 43 (37, 50)
Positive predictive value 60 (56, 64) 43 (36, 50) 69 (64, 74)
Negative predictive value 57 (52, 61) 79 (73, 83) 36 (30, 42)




Training Only selected staff were allocated time
if they haven’t completed the training,
Training/ access to equipment By the scheduled start date for the pilo
waiting on a RGBT meter and training
Length of assessment (pharmacy staff) Total health check more likely to take >
Therefore, an appointment often had t
Pharmacy staff If staff had limited time, often only a BP
Length of assessment (participants) Limited available time of participants a
assessments completed
Competency of staff carrying out health check
Pharmacy staff undertaking measures Health checks more likely to be perform
BP and AUSDRISK checks more likely to
Pharmacy staff attributes Concerns raised regarding confidence,
pharmacy assistant in carrying out RBG
When a pharmacy assistant performed
generally discussed with the pharmacis
Motivation Lack of motivation by staff limited how
was completed
Procedure
Space Limited number of pharmacies had a d
room to complete RBGT. General feelin
RBGT test in a pharmacy setting
Set up of a pharmacy in general was m
AUSDRISK assessment than a RBGT
Technique/participants Invasive nature of finger prick as part o
Some consumers refused waist measur
Safety and cost Concerns around appropriate disposal o
Purchase of consumables required to u
measures are expensive
Referral to GP If blood glucose level was >5.5 mmol a
something sweet to drink, staff reporte
to re-assess the participant at a later tim
If AUSDRISK score was high due to non
staff were less likely to refer
AUSDRISK: Australian type 2 diabetes risk assessment: BP: Blood pressure; RBGT: Ran
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prehensive assessment of their diabetes risk and CVD
risk status.
This is one of the largest studies to have used the
AUSDRISK tool in a pharmacy setting in Australia. The
use of the AUSDRISK is recommended as part of the
Australian National Evidence Based Guideline for the
Primary Prevention of Type 2 Diabetes [24]. The tool
has been validated in two independent Australian co-
horts (the Blue Mountains Eye Study of 2123 partici-
pants [25] and 4060 participants in the North West
Adelaide Health Study) [26]. AUSDRISK has also been





to complete the training. Therefore,
they may just completed BP check
✓ ✓
t phase, some pharmacies were still
regarding its use
✓
5 or <5 minutes >5 minutes <5 minutes
o be made to complete (>5 minutes)
check would be completed ✓ ✓
ffected the number of diabetes risk ✓ ✓
ed by fully trained pharmacist ✓
be completed by pharmacist assistants ✓
knowledge, skill and experience of a
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✓
AUSDRISK, high risk patients were
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often the diabetes risk assessment ✓ ✓
esignated ‘booth’ or private consulting
g that it was inappropriate to conduct
✓
ore conducive to completion of the ✓
f RBGT was a concern for some participants ✓ ✓
ement as part of AUSDRISK
f ‘sharps’ and ‘clinical waste’ involved in RBGT ✓
ndertake RBGT and for infection control ✓
nd the consumer had recently eaten or had
d that the may not refer, but rather request
e point
✓
-modifiable risk factors (eg age and gender) ✓
dom blood glucose testing; *BP/AUSDRISK/RBGT; ** BP/AUSDRISK.
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the AUSDRISK against results from a fasting blood test
or fasting oral glucose tolerance test. However, Wong
and colleagues found that the use of AUSDRISK in gen-
eral practice was low [28]. The Melbourne Diabetes Pre-
vention Study is using AUSDRISK for assessment of
eligibility for a randomized controlled trial [10] and will
be the first study to compare AUSDRISK with FIN-
DRISC as diabetes risk assessment tools. AUSDRISK is
also routinely used in the LIFE! program which has now
assessed diabetes risk for 8,412 people [29]. We provide
important new information on use of AUSDRISK as part
of a well-established health promotion program in the
community.
The Pilot KYN Diabetes Program was used to test two
approaches through offering AUSDRISK or AUSDRISK/
RBGT. We undertook a ‘per program’ analysis since this
was the most appropriate method for answering our re-
search questions in this pragmatic study. We found that
pharmacies offering AUSDRISK/RBGT attracted a
greater number of participants (n = 3,494 vs n = 1,989)
and more people who participated in diabetes risk as-
sessments (39% vs 31%, respectively), when compared to
pharmacies offering AUSDRISK only. It is unknown
whether participants were aware before being tested
which approach was being offered. Greater participation
in the approach in Group 1 (AUSDRISK/RBGT) may be
due to participant perceptions including the fact that
people may more strongly associate diabetes testing with
a finger prick test. A study conducted by Krass et al.
[16] found that implementation of a pharmacy screening
service based on an initial risk assessment followed by a
finger prick test was more cost effective in terms of
numbers diagnosed with diabetes than a risk assessment
only. The cost difference was driven by lower referral
rates and the higher uptake of referrals following the fin-
ger prick test. In our study we are unable to test this as
we have no follow-up data.
Random allocation of pharmacies was not stratified
and pharmacies could swap groups prior to commen-
cing. The pharmacies electing to move into Group 1
were predominantly National Diabetes Services Scheme
pharmacies seeking to learn a new skill and offer an add-
itional service to their customers (i.e. blood glucose test-
ing) or were currently offering blood glucose tests and
were keen to continue with this service. Some selection
bias was noted following review of these findings. There
was tendency for the more active pharmacies in the
KYN Program to be offering AUSDRISK/ RBGT (Group
1), and this may have positively influenced participation.
Using data from the KYN 2010 Program, Group 1 phar-
macies were more likely to have previously participated
in the Pilot KYN Diabetes Program (Group 1: 67%,
Group 2: 59%) and undertook greater volumes of checks(mean number of checks: Group 1: 157; Group 2: 62).
Future studies would need to stratify pharmacies by pre-
vious participation in KYN and participant volumes be-
fore randomisation in order to account for these
differences. Pharmacies should also be kept blinded to
options so there are no crossovers.
One of the primary purposes of the KYN Program is
the referral of potentially ‘high risk’ people to their gen-
eral practitioner. It is also about raising awareness of
stroke risk factors and diabetes. Overall, Group 1 had
greater participation and higher number of referrals for
participants with ‘high BP’ compared with Group 2 par-
ticipants. However, the participants in Group 2 with
‘high risk’ of diabetes were more likely to be recom-
mended to follow-up with a general practitioner com-
pared with Group 1 participants. Specifically in relation
to this study, staff of Group 2 pharmacies may have had
more time to discuss their results with participants and
provide referrals than those in Group 1. Another poten-
tial source of reporting bias is that the differences in
number of referrals between Group 1 and Group 2 could
be because the referral may have been given verbally by
pharmacy staff and not documented on the registration
log. The majority of staff also felt that the cut-off of the
RBGT for referral was too low at >5.5 mmol.L which
may have influenced referral rates. Future studies should
include information on why the participant was not re-
ferred, for example, if they already visit their doctor
regularly; are being managed for their current health
problem; or whether the participant refused a referral
letter.
As with all risk assessment tools, AUSDRISK and
RBGT have limitations. The AUSDRISK has been vali-
dated in several studies [25-27] and is recommended for
use in the Australian setting [24]. However, there is
emerging evidence that the cut-points chosen in our
pilot project of 5.6 for RBGT and 12+ for AUSDRISK
may be too insensitive for efficiently identifying people
who may go on to develop diabetes [10]. This means
that a larger number of people may have been consid-
ered as requiring a referral to their doctor, than was ac-
tually necessary, to ensure a cost-effective health
promotion program. In future reviews of the KYN pro-
gram it will be important that cut-points for referral re-
main consistent with evidence–based national guideline
recommendations or compelling new research relevant
to the field. This ensures that the most appropriate dia-
betes risk screening approaches suitable for the setting
in which they are applied are used, and that primary care
resource use is optimised (i.e. inappropriate referrals to
general practice are minimised).
The sensitivity and specificity of the RBGT against the
AUSDRISK was low. This may be because AUSDRISK
and RBGT are two different diabetes risk assessment
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betes within the next five years (future risk). RBGT can
be used to assess risk of having undiagnosed diabetes.
We found that two-thirds of participants were at high
risk of diabetes (defined as high AUSDRISK and or high
RBGT). When we compared the participants with high
AUSDRISK score two in three also had a high RBGT
level. When adjusted for age and gender there was an
association between the two measures. We found that
for every one point increase in AUSDRISK score there
was a half point increase in RBGT levels. The implica-
tions of these findings for a health promotion program
are that RBGT would not be a reasonable proxy for dia-
betes risk assessment (such as AUSDRISK) for 37% of
participants. To our knowledge there have been no other
studies that have compared RBGT and AUSDRISK tools.
The additional qualitative data provided evidence to
support the use of the AUSDRISK only instead of RBGT.
The RBGT and AUSDRISK approach (Group 1) required
more staff time and resources. Infection control proce-
dures, additional training and the extra consumables
required for RBGT make it less cost-effective for imple-
mentation by community pharmacists as part of a health
promotion program. A weakness of this pilot program
was that no formal cost-effectiveness evaluation or regis-
trant feedback on the different methods of assessing dia-
betes risk was conducted. Consumer feedback on
different methods of assessing diabetes risk was only in-
directly obtained from pharmacists who reported that
KYN registrants felt that RBGT was more invasive. The
roles of pharmacy assistants are important in the sus-
tainable role out of health promotion programs in phar-
macies, and there were common concerns with the skill,
experience and confidence of pharmacy assistants to
undertake a RBGT and the impracticalities of this meas-
ure. Alternatively, AUSDRISK is a simple and efficient
measure to assess people’s risk of diabetes in a commu-
nity setting.
The potential limitations of the KYN data have been
noted in previous publications in related to the KYN
Program [19,20]. In brief, the group of participants being
tested was a convenience sample and may not be repre-
sentative of the general population. In relation to this
study specifically, we were only able to assess diabetes
risk for around a third of the participants and for the
group tested for risk of diabetes we were unable to col-
lect outcome data on diabetes status. The pharmacist
recommendation is a proxy outcome for doctor attend-
ance and detection of undiagnosed diabetes or participa-
tion in the Life! Program. In order to fully compare the
two diabetes risk assessment measure (AUSDRISK and
RBGT) we need to know who actually developed dia-
betes. The pilot study could have been strengthened if it
had been possible to follow-up with general practitionersfor all ‘high-risk’ registrants that visited their doctor
based on the results of their KYN determined diabetes
risk status. Among KYN registrants who are referred to
their doctor, 85% have self-reported visiting their doctor
[19,20]. It would also have been strengthened if the results
from RBGT and AUSDRISK were compared to the gold
standard (e.g. fasting blood test or oral glucose tolerance
test) for a sample of participants and pharmacies (stratified
according to size, experience of staff to the Program). The
strengths of our study include the large sample of pharma-
cies and community-based participants.
Conclusions
The Australian Pilot KYN Diabetes Program provides
evidence of the feasibility and acceptability of a method
of raising community awareness of type 2 diabetes in
community pharmacy locations. Despite some advan-
tages and disadvantages of providing both diabetes tests
AUSDRISK alone was deemed to be the preferred
method since providing two tests added to the complex-
ity of the program for pharmacy staff. The program pro-
vided an opportunity for people to have their risk for
type 2 diabetes assessed and understand their results.
Participants classified at ‘high risk’ of diabetes were more
likely to be referred to their doctor for a comprehensive
assessment. As a result of the Pilot KYN Diabetes Pro-
gram a recommendation was made by the KYN Advis-
ory Committee to include a diabetes risk assessment
using the AUSDRISK in conjunction with BP testing as a
permanent feature of the KYN Program. In 2013, 40,780
KYN participants had received an AUSDRISK assess-
ment (46% of participants with high AUSDRISK score
12+) from approximately 1500 pharmacies across two
states (Queensland and New South Wales) of Australia.
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